Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Pär Stattin"'
Autor:
Marcus Westerberg, Kerri Beckmann, Rolf Gedeborg, Sandra Irenaeus, Lars Holmberg, Hans Garmo, Pär Stattin
Publikováno v:
Journal of Clinical Epidemiology. 155:22-30
Refereed/Peer-reviewed Objectives: To study how handling missing data on M stage in a clinical cancer register affects estimates of incidence of metastatic prostate cancer. Study Design and Setting: Estimates of age-standardized incidence of metastat
Autor:
Johan Syrjä, Mats Lambe, David Robinson, Irma Fredriksson, Pär Stattin, Rolf Gedeborg, Malin Sund, Hans Garmo, Anna Plym, Lars Holmberg
Publikováno v:
Epidemiology. 32:607-615
Background The ability to account for comorbidity when estimating survival in a population diagnosed with cancer could be improved by using a drug comorbidity index based on filled drug prescriptions. Methods We created a drug comorbidity index from
Autor:
Tanja Stocks, Sylvia H J Jochems, Marju Orho-Melander, Christel Häggström, Angela M. Wood, Pär Stattin
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2885-2896 (2021)
Cancer Medicine
Cancer Medicine
We recently found a negative association between body mass index (BMI) and the risk of localised prostate cancer (PCa), no association with advanced PCa, and a positive association with PCa‐specific mortality. In a 15% subpopulation of that study,
Autor:
Hendrick Van Poppel, Giorgio Gandaglia, Adam S. Kibel, Carlo La Vecchia, Freddie Bray, Neil Fleshner, Stephen J. Freedland, Pär Stattin, Riccardo Leni
Publikováno v:
European urology oncology. 4(6)
Context Worldwide, prostate cancer (PCa) represents the second most common solid tumor in men. Objective To assess the geographical distribution of PCa, epidemiological differences, and the most relevant risk factors for the disease. Evidence acquisi
Publikováno v:
Scandinavian Journal of Urology. 53:134-138
Objectives: To estimate the incidence of men seeking specialized care and receiving treatment for hydro or spermatocele complaints. Also, to determine the risk of complications of treatment.Materia...
Publikováno v:
BMJ Open. 12:e055485
ObjectiveTo estimate the additional risk of venous thromboembolism (VTE) in men with prostate cancer compared with men without prostate cancer in Sweden.DesignNationwide cohort study following 92 105 men with prostate cancer and 466 241 men without p
Publikováno v:
American Journal of Epidemiology
Net survival, estimated in a relative survival (RS) or cause-specific survival (CSS) framework, is a key measure of the effectiveness of cancer management. We compared RS and CSS in men with prostate cancer (PCa) according to age and risk category, u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07f1ed0c24a0e2aab9a6bb6ca1c45e3
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460914
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460914
Publikováno v:
Statistics in Medicine
It is imperative to understand the effects of early detection and treatment of chronic diseases, such as prostate cancer, regarding incidence, overtreatment and mortality. Previous simulation models have emulated clinical trials, and relied on extens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a190c5848555475b69c889bb24e295
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469809
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469809
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0255239 (2021)
PLoS ONE
PLoS ONE
Background The Charlson Comorbidity Index is a poor predictor of mortality in men with castration resistant prostate cancer (CRPC). To improve this prediction, we created a comorbidity index based on filled prescriptions intended to be used in regist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b32374fdb531bc2e7d9240c1750c591
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-453480
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-453480
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 10, p e0255966 (2021)
PLoS ONE, Vol 16, Iss 10, p e0255966 (2021)
Background Men have a higher risk of death from COVID-19 than women and androgens facilitate entrance of the SARS-CoV-2 virus into respiratory epithelial cells. Thus, androgen deprivation therapy may reduce infection rates and improve outcomes for CO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b7a7a4318ba0e5fcbce3829a252b83
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-188489
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-188489